n engl j med 364;26 nejm.org june 30, 2011 2558 toms among patients receiving omalizumab was clinically irrelevant, since a relative improvement of 24.5% in the symptom domain is clinically important and paralleled significant reductions in hospitalizations (74.6%), exacerbations (37.9%), and the daily dose of an inhaled glucocorticoid that was needed to maintain disease control (a reduction of 109 μg per day, or 14.1%). Most important, the seasonal peaks in asthma exacerbations were virtually eliminated. Therefore, in our opinion, the value of the clinical effect of this treatment should be assessed in relationship to the multiple domains of asthma morbidity.